Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alpha Tau Medical Ltd Cl A (DRTS)

Alpha Tau Medical Ltd Cl A (DRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alpha Tau Medical Ltd. Progresses with Alpha DaRT® as FDA Approves Key Trials and Financial Update Reveals Strong Cash Position

Alpha DaRT® enters FDA's TAP program, initiates studies for recurrent cancers, reports financial results, and maintains significant cash reserves.Quiver AI SummaryAlpha Tau Medical Ltd. announced significant...

DRTS : 2.30 (unch)
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

DRTS : 2.30 (unch)
DRTSW : 0.1717 (-14.79%)
Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference

DRTS : 2.30 (unch)
DRTSW : 0.1717 (-14.79%)
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

DRTS : 2.30 (unch)
DRTSW : 0.1717 (-14.79%)
Alpha Tau Treats First Patient with Recurrent Lung Cancer

DRTS : 2.30 (unch)
DRTSW : 0.1717 (-14.79%)
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

JERUSALEM, July 05, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the “Company”), the developer of the innovative...

DRTS : 2.30 (unch)
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™

/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced...

DRTS : 2.30 (unch)
Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site

/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha...

DRTS : 2.30 (unch)
Why Alpha Tau Medical Stock Skyrocketed Today

The stock enjoyed another big gain.

DRTS : 2.30 (unch)
Why Alpha Tau Medical Ltd. Stock Soared 42% on Wednesday

The company is developing a promising type of radiation treatment for solid tumors.

DRTS : 2.30 (unch)

Barchart Exclusives

Nasdaq Futures Tread Water as Investors Brace for Nvidia Earnings
December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.09% this morning as investors shifted their focus to a highly anticipated earnings report from AI darling Nvidia. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar